Lifeward Croissance future
Future contrôle des critères 2/6
Lifeward devrait augmenter ses bénéfices et ses revenus de 51.7% et de 38.6% par an respectivement, tandis que le BPA devrait croître de croître de 69.3% par an.
Informations clés
51.7%
Taux de croissance des bénéfices
69.33%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 17.0% |
| Taux de croissance des recettes | 38.6% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 26 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • Jun 18
LFWD: Long Term Safety Data Will Support Stock Upside Potential
Analysts have modestly adjusted their price target on Lifeward, keeping fair value steady at $20.00. They fine tuned assumptions around the discount rate, profit margin, and future P/E to reflect updated valuation work, without a clear directional shift in the overall outlook.Mise à jour du récit • Jun 04
LFWD: Higher Expected Revenue And Future P/E Multiple Will Support Upside
Analysts have raised their price target for Lifeward to $10 from $4.50, citing updated assumptions on revenue growth, profit margins, discount rate, and future P/E that support a higher valuation framework. What's in the News On May 15, 2026, Lifeward said it will not be able to file its next 10-Q by the SEC deadline, indicating a delay in its upcoming quarterly report.Mise à jour du récit • May 16
LFWD: Lower Discount Rate And Higher P/E Assumptions Support Upside Potential
Analysts have lifted their price target on Lifeward to $10 from $4.50, citing updated assumptions around discount rates, long term profit margins, and future P/E levels that feed into their fair value framework. Analyst Commentary Analysts revising their fair value frameworks for Lifeward point to changes in discount rates, long term margin assumptions, and targeted P/E levels as key drivers behind the new US$10 price target.
Mise à jour du récit • Apr 30
LFWD: Higher Fair Value Assumptions Will Shape Future P E Repricing
Analysts have raised their price target on Lifeward to $10 from $4.50, citing updated assumptions related to fair value, discount rate, revenue growth, profit margin and future P/E estimates. Analyst Commentary Bearish analysts describe the move to a US$10 price target as a recalibration rather than a clear vote of confidence, pointing out that the new target still reflects uncertainty around how Lifeward can deliver on the assumptions used in updated fair value work.
Mise à jour du récit • Apr 15
LFWD: Higher Risk Reward View Will Support Future Upside Potential
Analysts have raised their price target on Lifeward to $10 from $4.50, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple that together change their view of the company’s balance of risk and reward. Analyst Commentary Bullish analysts are framing the new US$10 price target as a reassessment of Lifeward’s potential risk and reward, rather than just a reaction to short term news.Mise à jour du récit • Mar 31
LFWD: Higher Fair Value Assumptions Will Support Future Cash Flow
Analysts have lifted the price target for Lifeward to $10 from $4.50, citing updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Analysts lifting the Lifeward price target to $10 from $4.50 are updating their view of what they see as fair value, based on refreshed assumptions for revenue growth, profitability, discount rates, and future P/E levels.Mise à jour du récit • Mar 17
LFWD: Reverse Split And Convertible Notes Will Support Future Upside
Analysts have raised their price target on Lifeward from $10.00 to about $120.00, citing updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Lifeward plans dedicated clinic days with Shirley Ryan AbilityLab in Chicago starting in the second quarter of 2026, focused on evaluation and access to the FDA cleared ReWalk Personal Exoskeleton for people with spinal cord injury (Key Developments).Mise à jour du récit • Mar 03
LFWD: Reverse Split And New Financing Will Support Future Cash Flow
Analysts have lifted their price target for Lifeward to $87.00, supported by updated assumptions around fair value, discount rate, revenue growth, profit margin, and a lower future P/E multiple. What's in the News Lifeward plans a 1 for 12 reverse split of its ordinary shares, effective at the open of trading on February 24, 2026.Mise à jour du récit • Feb 17
LFWD: Convertible Notes And Share Actions Will Drive Future P E Repricing
Analysts have modestly adjusted their price target on Lifeward, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E that slightly refine their view of the company’s risk and earnings power in dollar terms. What's in the News Lifeward plans a Special and Extraordinary Shareholders Meeting on March 12, 2026 at its Hudson, Massachusetts offices to address corporate matters previously approved in principle at earlier meetings (company event filing).Mise à jour du récit • Feb 03
LFWD: New Convertible Funding And Reverse Split Will Support Future Upside
Narrative Update on Lifeward Analysts have slightly reduced their price target for Lifeward, citing small adjustments to the discount rate and future P/E assumptions, along with modest changes to expected revenue growth and profit margins. What's in the News Lifeward completed a private placement on November 14, 2025, issuing secured convertible promissory notes with an aggregate principal of $3,000,000, carrying 15% annual interest and convertible into ordinary shares at $0.45 per share, with participation from Oramed Ltd and maturity on May 14, 2026 (Key Developments).Mise à jour du récit • Jan 20
LFWD: Future P/E Repricing Will Rely On Successful Convertible Note Execution
Analysts have raised their price target for Lifeward to reflect higher modelled revenue growth of about 53% and a very large future P/E multiple, even as they factor in a lower profit margin and a slightly higher discount rate. What's in the News Lifeward entered into a private placement agreement to issue Senior Secured Convertible Notes with a principal amount of $20,000,000 and accompanying warrants, with the notes initially convertible at $0.45 per share and accruing 8.0% annual interest that may rise to 15.0% in the event of default (Key Developments).Mise à jour du récit • Jan 06
LFWD: Reverse Split And New Funding Will Set Up Future Upside
Analysts have reduced their fair value estimate for Lifeward from US$13.00 to US$10.00. They attribute this change to more conservative assumptions on revenue growth, profit margins and the P/E multiple they apply to the company.Mise à jour du récit • Dec 17
LFWD: Improved Capital Structure Will Support Future Cash Flow Potential
Analysts have nudged their price target for Lifeward slightly higher to reflect marginally lower perceived risk and modest improvements in long term profitability and valuation assumptions, even as their underlying fair value estimate remains anchored around $5.17 per share. What's in the News Lifeward completed a $3 million private placement via secured convertible promissory notes bearing 15% interest, convertible at $0.45 per share and maturing May 14, 2026, with participation from Oramed Ltd.Mise à jour du récit • Dec 03
LFWD: Improved Medicare Reimbursement Trends Will Support Future Cash Flow
Narrative Update on Lifeward The analyst price target for Lifeward has been revised upward to approximately 5.17 dollars per share from 5.17 dollars previously. This reflects analysts' expectations for faster revenue growth, improved profit margins, and a lower future price to earnings multiple.Mise à jour du récit • Nov 19
LFWD: Rising Medicare Approvals And New Funding Will Support Revenue Outlook
Analysts have significantly lowered their price target for Lifeward from $8.00 to approximately $5.17. They cite more conservative revenue growth projections and a notable reduction in expected profit margins.Article d’analyse • Sep 25
Even With A 27% Surge, Cautious Investors Are Not Rewarding Lifeward Ltd.'s (NASDAQ:LFWD) Performance Completely
Despite an already strong run, Lifeward Ltd. ( NASDAQ:LFWD ) shares have been powering on, with a gain of 27% in the...Mise à jour du récit • Aug 16
FDA Clearance And Expanded Payer Channels Will Drive Advanced Mobility
The consensus price target for Lifeward has been revised down to $8.00, primarily reflecting a sharp decrease in its future P/E multiple, while profitability remains stable. What's in the News Lifeward reset full-year 2025 earnings guidance under new management, targeting revenue of $24–$26 million.Article d’analyse • Jun 19
Many Still Looking Away From Lifeward Ltd. (NASDAQ:LFWD)
With a price-to-sales (or "P/S") ratio of 0.5x Lifeward Ltd. ( NASDAQ:LFWD ) may be sending very bullish signals at the...Nouveau récit • May 11
AlterG NEO And ReWalk 70 Will Shape Future Market Opportunities
Established lump sum payments and expanded into U.S. workers' compensation, creating stable revenue streams and improving net margins through efficient claim processing.Article d’analyse • Feb 05
Market Cool On Lifeward Ltd.'s (NASDAQ:LFWD) Revenues Pushing Shares 50% Lower
Lifeward Ltd. ( NASDAQ:LFWD ) shareholders won't be pleased to see that the share price has had a very rough month...Article d’analyse • Oct 30
Not Many Are Piling Into Lifeward Ltd. (NASDAQ:LFWD) Stock Yet As It Plummets 25%
Unfortunately for some shareholders, the Lifeward Ltd. ( NASDAQ:LFWD ) share price has dived 25% in the last thirty...Article d’analyse • Oct 15
Here's Why Lifeward (NASDAQ:LFWD) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Article d’analyse • Aug 01
ReWalk Robotics Ltd. (NASDAQ:LFWD) Soars 26% But It's A Story Of Risk Vs Reward
ReWalk Robotics Ltd. ( NASDAQ:LFWD ) shareholders are no doubt pleased to see that the share price has bounced 26% in...Article d’analyse • May 30
Is ReWalk Robotics (NASDAQ:LFWD) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 78 | -11 | N/A | N/A | 2 |
| 12/31/2027 | 51 | -14 | N/A | N/A | 2 |
| 12/31/2026 | 28 | -24 | N/A | N/A | 2 |
| 3/31/2026 | 21 | -26 | -15 | -15 | N/A |
| 12/31/2025 | 22 | -20 | -17 | -17 | N/A |
| 9/30/2025 | 24 | -30 | -17 | -17 | N/A |
| 6/30/2025 | 24 | -30 | -18 | -18 | N/A |
| 3/31/2025 | 25 | -27 | -20 | -20 | N/A |
| 12/31/2024 | 26 | -29 | -22 | -22 | N/A |
| 9/30/2024 | 25 | -19 | -22 | -22 | N/A |
| 6/30/2024 | 23 | -24 | -25 | -25 | N/A |
| 3/31/2024 | 18 | -24 | -23 | -23 | N/A |
| 12/31/2023 | 14 | -22 | -21 | -21 | N/A |
| 9/30/2023 | 9 | -22 | -20 | -20 | N/A |
| 6/30/2023 | 6 | -20 | -17 | -17 | N/A |
| 3/31/2023 | 6 | -20 | -17 | -17 | N/A |
| 12/31/2022 | 6 | -20 | -18 | -18 | N/A |
| 9/30/2022 | 5 | -18 | -17 | -17 | N/A |
| 6/30/2022 | 6 | -15 | -15 | -15 | N/A |
| 3/31/2022 | 6 | -14 | -14 | -14 | N/A |
| 12/31/2021 | 6 | -13 | -12 | -11 | N/A |
| 9/30/2021 | 6 | -12 | -11 | -11 | N/A |
| 6/30/2021 | 5 | -12 | -11 | -11 | N/A |
| 3/31/2021 | 5 | -12 | -11 | -11 | N/A |
| 12/31/2020 | 4 | -13 | -13 | -13 | N/A |
| 9/30/2020 | 4 | -14 | -14 | -14 | N/A |
| 6/30/2020 | 5 | -14 | -14 | -14 | N/A |
| 3/31/2020 | 4 | -15 | -15 | -15 | N/A |
| 12/31/2019 | 5 | -16 | N/A | -15 | N/A |
| 9/30/2019 | 5 | -17 | N/A | -14 | N/A |
| 6/30/2019 | 6 | -18 | N/A | -14 | N/A |
| 3/31/2019 | 7 | -19 | N/A | -14 | N/A |
| 12/31/2018 | 7 | -22 | N/A | -15 | N/A |
| 9/30/2018 | 6 | -23 | N/A | -18 | N/A |
| 6/30/2018 | 7 | -24 | N/A | -20 | N/A |
| 3/31/2018 | 7 | -25 | N/A | -21 | N/A |
| 12/31/2017 | 8 | -25 | N/A | -22 | N/A |
| 9/30/2017 | 8 | -27 | N/A | -24 | N/A |
| 6/30/2017 | 7 | -29 | N/A | -25 | N/A |
| 3/31/2017 | 6 | -32 | N/A | -27 | N/A |
| 12/31/2016 | 6 | -33 | N/A | -27 | N/A |
| 9/30/2016 | 6 | -31 | N/A | -27 | N/A |
| 6/30/2016 | 5 | -30 | N/A | -27 | N/A |
| 3/31/2016 | 5 | -27 | N/A | -26 | N/A |
| 12/31/2015 | 4 | -25 | N/A | -25 | N/A |
| 9/30/2015 | 4 | -23 | N/A | -21 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: LFWD devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: LFWD devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: LFWD devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de LFWD ( 38.6% par an) devrait croître plus rapidement que le marché US ( 12.6% par an).
Croissance élevée des revenus: Le chiffre d'affaires de LFWD ( 38.6% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de LFWD devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/17 04:56 |
| Cours de l'action en fin de journée | 2026/07/17 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Lifeward Ltd. est couverte par 7 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Matthew Taylor | Barclays |
| William Plovanic | Canaccord Genuity |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |